← Global & Regional Health Technology Assessment
Papers in Global & Regional Health Technology Assessment
Page 1 · newest first
- Oncology drug expenditure governance in an antineoplastic drug unit: comparative economic analysis 2023–2025 and the stratified recovery rateGlobal & Regional Health Technology Assessment · 2026
- Implementing the EU HTA Regulation in Italy: a multi-stakeholder perspective from the Mogliano Veneto Working GroupGlobal & Regional Health Technology Assessment · 2026
- The role of osimertinib in the therapeutic pathway of EGFR-mutated NSCLC: results from an Italian Delphi ConsensusGlobal & Regional Health Technology Assessment · 2026
- AIFA monitoring registries as a strategic tool in the Italian HTA framework: evolution and policy implicationsGlobal & Regional Health Technology Assessment · 2026
- The patient’s perspective in the pharmaceutical regulatory and access pathway: considerations and recommendations from the 2025 Patient ForumGlobal & Regional Health Technology Assessment · 2026
- Exploring the current and future role of artificial intelligence in pharmaceutical market access: insights from a European surveyGlobal & Regional Health Technology Assessment · 2026
- Burden of primary biliary cholangitis on the Italian National Health Service: retrospective analysis from an administrative databaseGlobal & Regional Health Technology Assessment · 2026
- Pharmacoeconomic analysis of switch to faricimab for neovascular age-related macular degeneration in real clinical practiceGlobal & Regional Health Technology Assessment · 2026
- Impact of AIFA Note 100 on innovative antidiabetic prescribing eligibility in two Italian local health authorities: drug utilization and patient characteristicsGlobal & Regional Health Technology Assessment · 2026
- Impact of Ministerial Decree 77/2022 from different stakeholders’ perspectives: clinicians, pharmacists, patients, and industryGlobal & Regional Health Technology Assessment · 2026
- Optimizing CAR-T therapy delivery in the Italian healthcare system: economic and organizational insights in follicular lymphomaGlobal & Regional Health Technology Assessment · 2026
- Procedural activity and dynamics of the new Italian Scientific and Economic Committee (CSE): a one-year observational analysisGlobal & Regional Health Technology Assessment · 2026
- More and earlier data from AIFA: do they impact on the regional policies? Results from an exploratory analysisGlobal & Regional Health Technology Assessment · 2026
- Cost minimization analysis of subcutaneous and intravenous immunoglobulin treatment in ItalyGlobal & Regional Health Technology Assessment · 2026
- A guide to critical reading of influenza vaccine cost-effectiveness analysesGlobal & Regional Health Technology Assessment · 2026
- Italian Medicines Agency’s reform and time until pricing and reimbursement decisions: a time-to-event analysisGlobal & Regional Health Technology Assessment · 2026
- The societal costs associated with patients with chronic spontaneous urticaria (CSU) in ItalyGlobal & Regional Health Technology Assessment · 2026
- Non-profit research: an insight into the management and monitoring of clinical trials in ItalyGlobal & Regional Health Technology Assessment · 2026
- Use of artificial intelligence to draft a mini-HTA report on a new medical device belonging to class IIb–IIIGlobal & Regional Health Technology Assessment · 2026
- Erratum in: Exploring the administrative burden faced by hematologists: a comprehensive study in ItalyGlobal & Regional Health Technology Assessment · 2026
- Clinical and economic burden of migraine in Italy: a real-world evidence analysisGlobal & Regional Health Technology Assessment · 2026
- Erratum in: Economic evaluation of distribution modalities for ostomy and incontinence medical devices within the Italian healthcare contextGlobal & Regional Health Technology Assessment · 2026
- Differences in organizational impact, performance and quality related to the use of single- and/or reusable bronchoscopes in anesthesiology and resuscitationGlobal & Regional Health Technology Assessment · 2026
- Health technology assessment of an automated unitdose drug distribution system in a high-specialization national referral hospital of the Italian National Health ServiceGlobal & Regional Health Technology Assessment · 2026
- Optimising pediatric paracetamol and ibuprofen use: a retrospective study with expert evaluation of efficacy, safety, and healthcare costsGlobal & Regional Health Technology Assessment · 2025
- Economic consequences of the introduction of the JADA® device for the management of postpartum haemorrhage in ItalyGlobal & Regional Health Technology Assessment · 2025
- The economic impact of multimorbidity in Italy: evaluation of direct costs and scenario analysis of patients with type 2 diabetes, heart failure, and chronic kidney disease using real-world dataGlobal & Regional Health Technology Assessment · 2025
- RWE in oncology: use of databases to identify molecular subtypes of metastatic breast cancer in ItalyGlobal & Regional Health Technology Assessment · 2025
- Paving the road for a successful EU HTA Reform implementationGlobal & Regional Health Technology Assessment · 2025
- Micro-costing analysis from Italian Guidelines for the management of sporadic primary hyperparathyroidismGlobal & Regional Health Technology Assessment · 2025
- Health technology assessment (HTA) of prostatic urethral lift (PUL) for the treatment of benign prostatic hyperplasia (BPH) in the Italian contextGlobal & Regional Health Technology Assessment · 2025
- Cost-effectiveness analysis of nirmatrelvir/ritonavir in adult patients at high risk of progressing to severe COVID-19Global & Regional Health Technology Assessment · 2025
- Cost-effectiveness analysis of nirmatrelvir/ritonavir in adult patients at high risk of progressing to severe COVID-19Global & Regional Health Technology Assessment · 2025
- Cost-analysis from real-world REDS study on dalbavancin in inpatient treatment of acute bacterial skin and skin structure infectionsGlobal & Regional Health Technology Assessment · 2025
- Time to market evaluation for new chemical entities in Italy: a critical analysis of the period 2018-2024Global & Regional Health Technology Assessment · 2025
- Healthcare of patients with immunoglobulin A nephropathy through a retrospective observational study of Italian administrative dataGlobal & Regional Health Technology Assessment · 2025
- Cost-effectiveness of cenobamate as a therapeutic alternative for the treatment of focal epilepsy in adults with inadequate seizure controlGlobal & Regional Health Technology Assessment · 2025
- Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in ItalyGlobal & Regional Health Technology Assessment · 2025
- Assessing the economic burden of Waldenström’s Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL)Global & Regional Health Technology Assessment · 2025
- Optimization in the HIV treatment: economic and organizational impact analysis of Bictegravir/Emtricitabine/Tenofovir AlafenamideGlobal & Regional Health Technology Assessment · 2025
- Assessment and value of drugs: report of the focus groups from the XXII National Conference on PharmaceuticalsGlobal & Regional Health Technology Assessment · 2025
- Cost of illness of Heart Valve Diseases (HVDs): A real-world analysis in ItalyGlobal & Regional Health Technology Assessment · 2025
- Towards a Green Health Technology Assessment: embedding Life Cycle Assessment for sustainable choicesGlobal & Regional Health Technology Assessment · 2025
- Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in ItalyGlobal & Regional Health Technology Assessment · 2025
- Value contribution of leniolisib in the Treatment of Activated PI3Kδ syndrome (APDS) in Spain using Multi-Criteria Decision Analysis (MCDA)Global & Regional Health Technology Assessment · 2025
- What is needed to successfully implement the EU HTA Regulation enabling broad patient access in EuropeGlobal & Regional Health Technology Assessment · 2025
- The length of price&reimbursement negotiation procedures in Italy in the period 2021-2023 was independent from the price of medicinesGlobal & Regional Health Technology Assessment · 2025
- The economic burden of post-endoscopic retrograde cholangiopancreatography (ERCP) procedure infections in ItalyGlobal & Regional Health Technology Assessment · 2024
- Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage IV Hodgkin lymphoma in ItalyGlobal & Regional Health Technology Assessment · 2024
- A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapyGlobal & Regional Health Technology Assessment · 2024